


Fig. 1A
(prior art)




Fig. 1B




AmpR promoter
Bgl II (13)
AmpR
Pst I (1295)
ori
EASE
SV40 poly(A) signal
pMBL CE-GS
8974 bp
Eco RI (6009)
GS ORF
Pst I (5729)
Pst I (2761)
PGK promoter
SV40 poly(A) signal
pMBL C-RP1
pMBL C-RP2
CMV promoter
pmbl c RP
Sac I (4431)
Xho I (4576)
pmbl c FP
T7 promoter
Not I (4509)

Fig. 1C

Fig. 1D


Not I (4509)
T7 promoter
Xho I (4576)
pmbl c RP
pMBL C-RP2
pMBL C-RP1
SV40 poly(A) signal
PGK promoter
Pst I (5729)
GS ORF
Eco RI (6009)
SV40 poly(A) signal
AmpR
AmpR promoter
ori
Pst I (2761)
pmbl c FP
EASE
Sac I (4431)
Pst I (1295)
CMV promoter
Bgl II (13)
pMBL CE-GS
8974 bp

GGGTAGGGGAGGCGCTTTTCCCAAGGCAGTCTGGAGCATGCGCTTTAGCAGCCCCGCTGGGCAC
TTGGCGCTACACAAGTGGCCTCTGGCCTCGCACACATTCCACATCCACCGGTAGGCGCCAACCG
GCTCCGTTCTTTGGTGGCCCCTTCGCGCCACCTTCTACTCCTCCCCTAGTCAGGAAGTTCCCCC
CCGCCCCGCAGCTCGCGTCGTGCAGGACGTGACAAATGGAAGTAGCACGTCTCACTAGTCTCGT
GCAGATGGACAGCACCGCTGAGCAATGGAAGCGGGTAGGCCTTTGGGGCAGCGGCCAATAGCAG
CTTTGCTCCTTCGCTTTCTGGGCTCAGAGGCTGGGAAGGGGTGGGTCCGGGGGCGGGCTCAGGG
GCGGGCTCAGGGGCGGGCGGGCGCCCGAAGGTCCTCCGGAGGCCCGGCATTCTGCACGCTTCA
AAAGCGCACGTCTGCCGCGCTGTTCTCCTCTTCCTCATCTCCGGGCCTTTCTCGATGGCCACCT
CAGCAAGTTCCCACTTGAACAAAAACATCAAGCAAATGTACTTGTGCCTGCCCCAGGGTGAGAA
AGTCCAAGCCATGTATATCTGGGTTGATGGTACTGGAGAAGGACTGCGCTGCAAAACCCGCACC
CTGGACTGTGAGCCCAAGTGTGTAGAAGAGTTACCTGAGTGGAATTTTGATGGCTCTAGTACCT
TTCAGTCTGAGGGCTCCAACAGTGACATGTATCTCAGCCCTGTTGCCATGTTTCGGGACCCCTT
CCGCAGAGATCCCAACAAGCTGGTGTTCTGTGAAGTTTTCAAGTACAACCGGAAGCCTGCAGAG
ACCAATTTAAGGCACTCGTGTAAACGGATAATGGACATGGTGAGCAACCAGCACCCCTGGTTTG
GAATGGAACAGGAGTATACTCTGATGGGAACAGATGGGCACCCTTTTGGTTGGCCTTCCAATGG
CTTTCCTGGGCCCCAAGGTCCGTATTACTGTGGTGTGGGCGCAGACAAAGCCTATGGCAGGGAT
ATCGTGGAGGCTCACTACCGCGCCTGCTTGTATGCTGGGGTCAAGATTACAGGAACAAATGCTG
AGGTCATGCCTGCCCAGTGGGAATTCCAAATAGGACCCTGTGAAGGAATCCGCATGGGAGATCA
TCTCTGGGTGGCCCGTTTCATCTTGCATCGAGTATGTGAAGACTTTGGGGTAATAGCAACCTTT
GACCCCAAGCCCATTCCTGGGAACTGGAATGGTGCAGGCTGCCATACCAACTTTAGCACCAAGG
CCATGCGGGAGGAGAATGGTCTGAAGCACATCGAGGAGGCCATCGAGAAACTAAGCAAGCGGCA
CCGGTACCACATTCGAGCCTACGATCCCAAGGGGGGCCTGGACAATGCCCGTCGTCTGACTGGG
TTCCACGAAACGTCCAACATCAACGACTTTTCTGCTGGTGTCGCCAATCGCAGTGCCAGCATCC
GCATTCCCCGGACTGTCGGCCAGGAGAAGAAAGGTTACTTTGAAGACCGCCGCCCCTCTGCCAA
TTGTGACCCCTTTGCAGTGACAGAAGCCATCGTCCGCACATGCCTTCTCAATGAGACTGGCGAC
GAGCCCTTCCAATACAAAAACTAA

Fig. 2A: SEQ ID NO: 1

GGGTAGGGGAGGCGCTTTTCCCAAGGCAGTCTGGAGCATGCGCTTTAGCAGCCCCGCTGGGCACTT
GGCGCTACACAAGTGGCCTCTGGCCTCGCACACATTCCACATCCACCGGTAGGCGCCAACCGGCTC
CGTTCTTTGGTGGCCCCTTCGCGCCACCTTCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCC
CGCAGCTCGCGTCGTGCAGGACGTGACAAATGGAAGTAGCACGTCTCACTAGTCTCGTGCAGATGG
ACAGCACCGCTGAGCAATGGAAGCGGGTAGGCCTTTGGGGCAGCGGCCAATAGCAGCTTTGCTCCT
TCGCTTTCTGGGCTCAGAGGCTGGGAAGGGGTGGGTCCGGGGGCGGGCTCAGGGGCGGGCTCAGGG
GCGGGGCGGGCGCCCGAAGGTCCTCCGGAGGCCCGGCATTCTGCACGCTTCAAAAGCGCACGTCTG
CCGCGCTGTTCTCCTCTTCCTCATCTCCGGGCCT

Fig. 2B: SEQ ID NO: 2

ATGGCCACCTCAGCAAGTTCCCACTTGAACAAAAACATCAAGCAAATGTACTTGTGCCTGCCCC
AGGGTGAGAAAGTCCAAGCCATGTATATCTGGGTTGATGGTACTGGAGAAGGACTGCGCTGCAA
AACCCGCACCCTGGACTGTGAGCCCAAGTGTGTAGAAGAGTTACCTGAGTGGAATTTTGATGGC
TCTAGTACCTTTCAGTCTGAGGGCTCCAACAGTGACATGTATCTCAGCCCTGTTGCCATGTTTC
GGGACCCCTTCCGCAGAGATCCCAACAAGCTGGTGTTCTGTGAAGTTTTCAAGTACAACCGGAA
GCCTGCAGAGACCAATTTAAGGCACTCGTGTAAACGGATAATGGACATGGTGAGCAACCAGCAC
CCCTGGTTTGGAATGGAACAGGAGTATACTCTGATGGGAACAGATGGGCACCCTTTTGGTTGGC
CTTCCAATGGCTTTCCTGGGCCCCAAGGTCCGTATTACTGTGGTGTGGGCGCAGACAAAGCCTA
TGGCAGGGATATCGTGGAGGCTCACTACCGCGCCTGCTTGTATGCTGGGGTCAAGATTACAGGA
ACAAATGCTGAGGTCATGCCTGCCCAGTGGGAATTCCAAATAGGACCCTGTGAAGGAATCCGCA
TGGGAGATCATCTCTGGGTGGCCCGTTTCATCTTGCATCGAGTATGTGAAGACTTTGGGGTAAT
AGCAACCTTTGACCCCAAGCCCATTCCTGGGAACTGGAATGGTGCAGGCTGCCATACCAACTTT
AGCACCAAGGCCATGCGGGAGGAGAATGGTCTGAAGCACATCGAGGAGGCCATCGAGAAACTAA
GCAAGCGGCACCGGTACCACATTCGAGCCTACGATCCCAAGGGGGGCCTGGACAATGCCCGTCG
TCTGACTGGGTTCCACGAAACGTCCAACATCAACGACTTTTCTGCTGGTGTCGCCAATCGCAGT
GCCAGCATCCGCATTCCCCGGACTGTCGGCCAGGAGAAGAAAGGTTACTTTGAAGACCGCCGCC
CCTCTGCCAATTGTGACCCCTTTGCAGTGACAGAAGCCATCGTCCGCACATGCCTTCTCAATGA
GACTGGCGACGAGCCCTTCCAATACAAAAACTAA

Fig. 2C: SEQ ID NO: 3

GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGT
CTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGT
CGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGC
AGAGCT

Fig. 2D: SEQ ID NO: 4

GATCTAATTCTGAACTTTTCTTTTGTTCCCTTCCCTTCTACCACACCCTAATTGTAATCCATTTTA
ATTTCCTGGTCACAGTCCTGTCTCTCCTTCCATTGTACCTTGCCCTTTTCTAAAGAGCGACTGCAA
AGTATGTTTGCGTAGGTGAGGATCTAAAACTTTATGAGGTACGAACATCACAGAATTACTTTGTAA
TTTCAGTTTATTGTAGGCTTGGCTTTTTGGGGAGGGTTTACGTCTTAGACCTCTTAGTGCTTCTTT
GTTTCATGGTGTTCTAACTTCGAAGCATCTCTGTAGCTTTAATGGATTCCTTTTCTGAAAGCTTTG
CTCTCTTTCTTCCCCCTCGGCTTTCTCTTAGGCAAGAGGGCTAACTGTAAAGTAAGGCTTACTGCC
TTGTGTTTCCAAATGTGTCCGAAGAGGAAGTGTCTTCTGTGAATCCTGTTATGCATGAATAACAGG
AAATAGAAAGAAATTCACTTTCATTATTATAAAAGTAATATGTTCGTTTAAAAAATTCTAATGAAG
AGCTGGAGATGCAACCCAGGGGTAGAGCACACACTCAGCATGCAGGAGGCCCTGGGTCCAATCTTG
GAATCTCCTCTCAGTTAACCTGATCTCTAGCTGATTAGTAGTGAGTGCAAGCCCACTTTCCTCTTC
TGCCTCATTGCTCAGTGATAACAGCTGTTAAACTTTGTCTTATTCTAAAACTACCTCTGTGCAAAT
GCTAGCACAATAATATATATCATATGCACATGATTTTTTTTTTATCTTGAAAAGTAAGTCAGTATA
GCTACAAAGTTCACTTGGCATTGTCAACATTTCACAGGCGTAATATTCCTCCTCTAGTACTGTCCT
CTTCATTCTTTGTGACCAAGTTTGGAGAGAGTGCACAAATGCCAGGGAGGTTTGTGGGAAGGTTTC

Fig. 2E: SEQ ID NO: 14 (continued)

TCATGTTCTGGTAAGGCGAGTAAGAAAATAGTCTCATGCAGGTGAAATGAGTGCTATGCAGTATAT
ATTATACCAGAGAACAGCAAATGACCAAATTCACACTGAACTAGTTCAGTAAAATTGGCTTTGTCA
AAGCTTTCCTTGCTTAAAATGTAATTCCCTGTCATCCTAGTTCTGGTCTGGATTCTTTTCCTGGAG
TCTTGACTTCCAGATTCCCTGTGGACTTTTGTTTGAGTTTCAAGCTTTTGAAATATAGAAACCTAT
CTAACTTAACAAACTTGGGAGAGAAAAGACTCCAGAACAACTGAAAACAGACCAGGCTAAATGAAT
AGACTTTATTCCTCTCTTCTTACCTGCAGTTTTCAGATATGCAGAGTTGGAGCGGATCTTAGAGGT
TGATTCATTCATGCCTGAAGAAAACACATTTTATAGACCCTGTGCCCAAGTTCGTGGTGGACATCA
CCCTTTATTTACTAATTGCACTACATAACAGGCATTTTAGAAGACTGCTCCAGTCAGAGACCCCGC
CTTAGAGGAATCTGTAAACCCTGAACTCCTATCACTCATGAGCACTAGTTATGTTTGGAATGCCGT
ATTAAAACAAAAGTTACATTTCTAAACTTAAAATTTTCTAGCACAGAGACAGTGGGAGTAGCTAAC
TTTGATAGACATTTTTCTACTAAAAGTCTTTCTAAGTACATAATCTTCTGTAAGTTGGAAAACAGC
AAAATAGAACGTCTCCTACGTAGTTAATCTTTTTGCATAATTTGCACATGTAGGAGTTATTAGTAT
ACGGGTAAGTTTTCACTTTTTCCCCCAACTGGAGTGTCTTGTGGCTGGGTTTGAAAAAGGGAACGG
GAGGCCGCTGGAGGGGATTGGTAAATGAGATAAAACACCACTCATTCAACTCAGTGACTCAGCATT
TAAATTTTCCATAAAAGGATTAAAGGAAAATTAAACAAATTCTTAAAGCCAAGACTCTGGAGAAAC
TTGTTGGTGTGCTTTAGTTTTCACTGTTATGACTCATGAATTTATGCATAAATTAGTACATTTATA
AAAACATAGCCTTTTTAGAGTTTTCTGTTTGGCTAAAGTGCCATTGTTAGCATTTGGAATTACCTT
TTTATGTCTTATATTTTTTCCAAATAAAAATAAATGTTTCTGCTGTCTTACTACTGAAACTACGTT
GTGAGCACTTTAAATTTCTCAAAGCAGTTTCGCCTGTTATACTTGGCGCTTAGTCATCGTCGTACA
CAACAGGACCTGATTAAGAAGGCTGTGCTGCCTCTAAGCCGGGCTAGATTGTAGCCACTAGCAACC
AGGCTGCAATAATTTCCCTTTGATGACATCATCCACTGTGGAAGAACCCAGTTGCTTCAGCCAGTC
GAACTATACAGTTCCAACCTCATCAAATATGGCATCTCCCTTGCCTGCTATAGCAGGGGGAGGAAA
AAATGCCACCATCTTTTTAATCTAGCAAGCTTCTCTTTTCTTCATCTTTTTTTTTTTCTTTTAAAA
AAATTCTGATCATGGATGCTTCTTCCGATCCCTATTTGCCTTATGACGGGGGAGGAGACAATATCC
CCTTGAGGGAATTACATAAAAGAGGTAAGAGCATCCCCTTGCTCTGAATCCTCTGTTGGTTGTTGT
GCATGCGGCTGGGCGGTTCTGGGGACAGGCTGTCTGTTGTCCTCTTGCTGCAATGTGCTGCTTAGT
TGCCCTGCCTTGTTGCTGTGGGAGAATGCGACCTTCCCAGCAGGGCTGGCCCTCCCTGATTGTTTG
CTCTGTGCAGATTAGCCCTGCTTCAGATCACATAGGGCTGCAGACTCCATCTTCTGTGTGAAAATG
CTTTCGGTTTGATTGCAGAAATAAGCTGCCTTTACAGCCAGCTAAAGTCCTGGTGGTTGGTTGGCA
CCTGCAAAGTAGTATTTTTGTACCTCTGGAAACTTATATTTTCTTTACACAGCAATATCAAGTGCC
GGTATGCCATTCTGTTTTGGCTGCTGCCAATTACCATGTAGACTTTGCACCACAGAGTAATAGTAA
AAGCTCCTAGCTGCATTTTATAACATTTAAAAATAGCAGGAAAGAAGAATTATTTTTGATTTAACA
TGTTTTTGTCATTTAACGTCTTAACTGATTGACATACTATATTGTCTGTCTCGTGGGTATCTTGTA
CAACTTGATAGGATAAAGCAATTTAGTTTTTTTTTTTTTTTTAAATACATCCAGAATGTAAGTCG
TCAGTAGTTTTCGAACAGATAAGTAATGGTGTTAATCTTTTGGCAGGCTTTGCCTTGGTCTCCTTA
AAGCTAATTAGGTGTTACTTAATTAAACTGCTCTTTTGCTCATTTTCTTAAATTATTTTTTTAAAA
GATAGTTGGCATTTGCTGTTCTAGAAATAAACTTCAAGAAACATTCTTTAGCCAGATGACTTCATG
TATGAGCCATGTTAGTTTGAATTATTTGCTTGGTGTTATAAACTTTATGGTTTAATACCAACTTTT
ATTATGTTTACAAGGTAAATAAGGAAAATTTCAAGTACATTTTGTATCCTGAGAACAAATTTAAGT
TCCATAGAATTTAGGAATTACAATGTATTCAACAGATACTTACTTGTCATACTGTGCCTGCAAAAC
AATAATTAGACTCTGAACAGGTGCAACAATTTTCTGTAGAATTG

Fig. 2E: SEQ ID NO: 14




AmpR promoter
AmpR
BglII (13)
NdeI (761)
ori
EASE
SmaI (6340)
XbaI (6092)
Puromycin
XbaI (4872)
SalI (4865)
SV40 poly(A) signal
pMBL C RP
XbaI (4582)
XhoI (4576)
BamHI (4538
T7 promoter
NotI (4509)
pMBL C FP
CMV promoter
pMBL CE-Puro
8331 bp
XbaI (3333)
NruI (3821)
NdeI (4097)

Fig. 3

Fig. 4


AmpR promoter
BglII (13)
NruI (213)
NdeI (489)
AmpR
CMV promoter
T7 promoter
NotI (901)
BamHI (930)
XhoI (968)
XbaI (974)
SV40 poly(A) signal
SalI (1257)
XbaI (1264)
pMBL C-Puro
4723 bp
ori
SmaI (2732)
XbaI (2484)
PUR CDS FP
Puromycin



PLB0087 6-uncut
PLB0087 6-BglII
PLB0087 6-PvuI+BglII
PLB0087 6-NruI+SalI
1Kbp DNA ladder
PLB0087 6-BamHI+EcoRI
PLB0087 6-NotI+EcoRI
PLB0087 6-SacI+EcoRI
PLB0087 6-XhoI+SmaI
1
2
3
4
5
6
7
8
9

Fig. 5A



1 PLB00942-BglII
2 PLB00942 - XbaI
3 PLB00942 - SmaI + SalI
4 PLB00942 - NdeI
5 PLB00942 - Uncut
6 1 Kb DNA ladder

Fig. 5C



1 PLB00915-Uncut
2 PLB00915-BglII
3 PLB00915-NruI+EcoRI
4 1Kbp DNA ladder
5 PLB00915-NruI+BglII
6 PLB00915-BsiZ17I
7 PLB00915-NdeI

Fig. 5B




Fig. 5D

mAb Codes	mAb description	Fusion details	Fusion location
Bmab700	Anti-CTLA4 (Yervoy)	-	(Biosimilar)
Fmab 25	Anti-CD20 fusion	Anti-CD20 mAb + TGFβRII ECD	Fusion at HC C-terminal
Fmab 26	Anti-CD20 fusion	Anti-CD20 mAb+ TGFβRII ECD	Fusion at LC C-terminal
Fmab 27	Anti-CD20 fusion	Anti-CD20 mAb+ TGFβRII ECD	Fusion at HC N-terminal
Fmab 28	Anti-CD20 fusion	Anti-CD20 mAb+ TGFβRII ECD	Fusion at LC N-terminal

Fig. 6



Titer [mg/L]
700
600
500
400
300
200
100
0
5
7
9
12
14
15
Days in culture [days]

Fig. 7A




Titer - mg/L
350
300
250
200
150
100
50
0
Fmab25
Fmab26
Fmab27
Fmab28
Fusion mAb code

Fig. 7B


Fig. 8A
VCD (X10^6 cells/ml)
16
12
8
4
0
Fmab 25/1
Fmab 25/2
Fmab 26/1
Fmab 26/2
Fmab 27/1
Fmab 27/2
Fmab 28/1
Fmab 28/2
Fmab Construct name




% Viability
100
60
20
-20
Fmab 25/1
Fmab 25/2
Fmab 26/1
Fmab 26/2
Fmab 27/1
Fmab 27/2
Fmab 28/1
Fmab 28/2
Construct Name

Fig. 8B


Fig. 8C
Titer (mg/L)
400
300
200
100
0
Fmab 25/1
Fmab 25/2
Fmab 26/1
Fmab 26/2
Fmab 27/1
Fmab 27/2
Fmab 28/1
Fmab 28/2
Construct Name




Fig. 8D




Fig. 9A







Fig. 9B


Fig. 9C
Titre [mg/L]
300
200
100
0
5
7
9
5
7
9
5
7
9
Anti CD-20 Wild Type
Fmab25
Fmab30
Construct Names


Fig. 9D
Titre [mg/L]
300
200
100
0
250
250
90
Anti CD-20 Wild Type
Fmab25
Fmab30
Construct Names


Fig. 10A
VCD (X 10^6 cells/ml)
14
12
10
8
6
4
2
0
Day 0
Day 2
Day 5
Day 7
Day 9
Day 12
Days in culture




Fig. 10B




Fig. 10C




Fig. 11A




Fig. 11B




Fig. 11C




Fig. 11D




Fig. 12A







Fig. 12B


Fig. 13A
VCD(x10^6 cells/ml)
12
8
4
0
0
3
5
7
10
12
14
Days in culture
3B
3A
2A
2A
2B


Viability (%)
100
80
60
40
20
0
0
3
5
7
10
12
14
Days in culture
2A
2B
3A
3B
Fig. 13B


Fig. 13C
Titer (mg/l)
400
300
200
100
0
5
7
10
14
Pool 2A
Pool 2B
Pool 3A
Pool 3B
Stable Pool ID




Fig. 13D




Fig. 14A






Fig. 14B


Fig. 14C
Titer (mg/l)
400
200
0
12
12
12
12
7
7
7
7
Pool 2A
Pool 2B
Pool 3A
Pool 3B
ID


Fig. 14D
Titer (mg/l)
400
200
0
462
465
318
348
Pool 2A
Pool 2B
Pool 3A
Pool 3B
ID



Fed Batch
(day 12)
Simple Fed Batch
(day 14)
Pool 2A
Pool 2B
Pool 3A
Pool 3B
Enbrel 500mg
Pool 2A
Pool 2B
Pool 3A
Pool 3B
Marker kDa
1
2
3
4
5
6
7
8
9
10

Fig. 15